ClinicalTrials.gg
CompletedNCT03615183Updated Sep 28, 2020Results posted

A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)

A Phase 1 interventional study of MK-8527 in Human Immunodeficiency Virus and AIDS Virus, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in Romania. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-09-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Acquired Immunodeficiency Syndrome by Merck & Co., Inc — 4 open to participants now, 6 under way, 3 of them phase 3. Acquired Immunodeficiency Syndrome · Merck & Co., Inc.

Enrollment
22nd of 34
17 · median 82
Started
2019
the only one that year
Phase 1
11 of 37
1 open now
Registered
22nd of 37
by date

Among the 37 studies in Acquired Immunodeficiency Syndrome by Merck & Co., Inc, this one is the 22nd largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2019, is one of 11 in phase 1, and was the 22nd registered.

Acquired Immunodeficiency Syndrome

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

4 of the 37 studies in Acquired Immunodeficiency Syndrome by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Acquired Immunodeficiency Syndrome by Merck & Co., Inc, or all of them as a file.
02

Study summary

This study will evaluate the anti-retroviral activity of MK-8527 in HIV-1 infected, ART-naïve participants. The primary hypothesis is that MK-8527 has superior anti-retroviral activity compared to placebo, as measured by change from baseline in plasma HIV-1 ribonucleic acid (RNA) at 168 hours postdose.

Read the detailed description

Up to five panels (Panels A-E) of 6 participants each will be enrolled in a sequential manner. In each panel, participants will receive a single dose of MK-8527 up to 50 mg. Historical data from previous single does studies will be used for placebo (control) comparisons.

03

Conditions studied

  • Human Immunodeficiency Virus
  • AIDS Virus
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Other than infection, is in good health
  • Is documented HIV-1 positive
  • Diagnosed with HIV-1 infection ≥ 3 months prior to screening or perform the French 2008 Haute Autorité de Santé (HAS) Algorithm to confirm chronic HIV.
  • Is ART-naïve which is defined as having never received any antiretroviral agent or the following: ≤30 consecutive days of an antiretroviral agent, excluding an Nucleoside reverse transcriptase inhibitors (NRTI), or ≤60 consecutive days of combination ART not including an NRTI
  • Has not received an investigational agent or marketed ART within 30 days of study drug administration
  • Is willing to receive no other ART for the monitoring period of the study
  • Has a (BMI) ≤35 kg/m\^2, inclusive
  • If the male participant has a female partner(s) of , he must agree to use a medically acceptable method of during the study and for 120 days after the last dose of study drug. If their partner is pregnant, males must agree to use a condom and no additional method of contraception is required for the pregnant partner
  • If the participant is a female with , she must demonstrate a serum β-human chorionic gonadotropin (β-hCG) level consistent with the nongravid state at the prestudy (screening) visit and agree to use (and/or have their partner use) 2 acceptable methods of birth control beginning at the prestudy (screening) visit, throughout the study (including washout intervals between treatment periods/panels) and until 28 days after the last dose of study drug.
  • If the participant is a female: she is without menses for at least 1 year and have a documented follicle stimulating hormone (FSH) level in the postmenopausal range at prestudy (screening)
  • If the participant is a surgically sterile female: she is status posthysterectomy, or oophorectomy

Exclusion criteria

Exclusion Criteria

  • Has a history of endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological (outside of -1 infection), renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. Participants with a remote history of uncomplicated medical events (eg, uncomplicated kidney stones, as defined as spontaneous passage and no recurrence in the last 5 years, or childhood asthma) may be enrolled in the study at the discretion of the investigator.
  • Is mentally or legally incapacitated at the time of the prestudy (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder over the last 5 years. Participants who have had situational depression may be enrolled in the study at the discretion of the investigator.
  • History of cancer ()
  • History of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability (i.e. systemic allergic reaction) to prescription or non-prescription drugs or food.
  • Positive for surface antigen
  • History of chronic unless there has been documented cure and/or participant with a positive serologic test for hepatitis C virus (HCV) has a negative HCV viral load (VL)
  • Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks
  • Unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study drug, throughout the study, until the poststudy visit.
  • Participated in another study within 4 weeks
  • Consumes greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spirits [29.5 mL/1 ounce]) per day.
  • Consumes excessive amounts, defined as greater than 6 servings (1 serving approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day
  • Is an excessive smoker (i.e., more than 10 cigarettes/day) and is unwilling to restrict smoking to ≤10 cigarettes per day
  • Has a positive urine drug screen
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Panel A: 10 mg MK-8527

    Single oral dose of 10 mg MK-8527 capsule after an 8-hour fast

    Drug: MK-8527

  • Experimental
    Panel B: 3 mg MK-8527

    Single oral dose of 3 mg MK-8527 capsule after an 8-hour fast

    Drug: MK-8527

  • Experimental
    Panel C: 1 mg MK-8527

    Single oral dose of 1 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.

    Drug: MK-8527

  • Experimental
    Panel D: ≤50 mg MK-8527

    Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.

    Drug: MK-8527

  • Experimental
    Panel E: ≤50 mg MK-8527

    Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.

    Drug: MK-8527

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Plasma HIV-1 RNA

    Blood samples were taken to determine HIV-1 RNA levels at Predose (baseline) and 168 hours postdose. Data were fitted with a longitudinal data analysis (LDA) model containing fixed effects for treatment, time and treatment by time interaction, and a random effect for participant.The change from baseline in plasma HIV-1 RNA in participants administered MK-8527 was calculated and results were compared with historical placebo data.

    Time frame: Baseline and 168 hours postdose

  2. Percentage of Participants Who Report 1 or More Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it is considered related to the medicinal product. The percentage of participants that reported at least 1 AE will be summarized.

    Time frame: Up to 28 days

  3. Percentage of Participants Who Were Discontinued From the Study Due to an AE

    An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it is considered related to the medicinal product. The percentage of participants that were discontinued from the study due to an AE will be summarized.

    Time frame: Up to 28 days

Secondary outcomes

  1. Area Under the Concentration Time Curve From Hour 0 to 168 Hours (AUC0-168) of MK-8527-TP in Peripheral Blood Mononuclear Cells (PBMC)

    Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-168 of MK-8527-triphosphate (MK-8527-TP) in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% confidence intervals (CI) for the means were constructed on the natural log scale and referenced the t-distribution.

    Time frame: Predose and 4, 12, 24, 96, 120, 144, and 168 hours postdose

  2. Area Under the Concentration Time Curve From Hour 0 to Last (AUC0-last) of MK-8527-TP in PBMC

    Blood samples were taken at Predose, up to approximately 28 days postdose to determine the AUC0-last of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

    Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 240, 336, 504, 672 hours or 28 days postdose

  3. Area Under the Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-8527-TP in PBMC

    Blood samples were taken at Predose, up to approximately 28 days postdose to determine the AUC0-Inf of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

    Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 240, 336, 504, 672 hours or 28 days postdose

  4. Maximum Concentration (Cmax) of MK-8527-TP in PBMC

    Blood samples were taken at Predose, up to approximately 28 days postdose to determine the Cmax of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

    Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 240, 336, 504, 672 hours or 28 days postdose

  5. Time to Cmax (Tmax) of MK-8527-TP in PBMC

    Blood samples were taken at Predose, up to approximately 28 days postdose to determine the Tmax of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

    Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 240, 336, 504, 672 hours or 28 days postdose

  6. Concentration at 168 Hours (C168) of MK-8527-TP in PBMC

    Blood samples were taken at 168 hours postdose to determine the C168 of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

    Time frame: 168 hours postdose for each panel

  7. Apparent Terminal Half Life (t1/2) of MK-8527-TP in PBMC

    Blood samples were taken at Predose, up to approximately 28 days postdose to determine the t1/2 of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

    Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 240, 336, 504, 672 hours or 28 days postdose

  8. Area Under the Concentration Time Curve From Hour 0 to 168 Hours (AUC0-168) of MK-8527 in Plasma

    Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-168 of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose

  9. Area Under the Concentration Time Curve From Hour 0 to Last (AUC0-last) of MK-8527 in Plasma

    Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-last of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose

  10. Area Under the Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-8527 in Plasma

    Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-inf of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose

  11. Maximum Concentration (Cmax) of MK-8527 in Plasma

    Blood samples were taken at Predose, up to 168 hours postdose to determine the Cmax of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose

  12. Time to Cmax (Tmax) of MK-8527 in Plasma

    Blood samples were taken at Predose, up to 168 hours postdose to determine the Tmax of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose

  13. Concentration at 168 Hours (C168) of MK-8527 in Plasma

    Blood samples were taken at 168 hours postdose to determine the C168 of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

    Time frame: 168 hours postdose

  14. Apparent Terminal Half Life (t1/2) of MK-8527 in Plasma

    Blood samples were taken at Predose, up to 168 hours postdose to determine the t1/2 of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose

07

Results

Posted Sep 28, 2020

Participant flow

Anti-retroviral therapy (ART)-naïve, participants with human immunodeficiency type 1 virus (HIV-1) infection were enrolled in this study.

Participant flow — Overall Study
MilestonePanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mgPanel D: ≤50 mg MK-8527Panel E: ≤50 mg MK-8527
Started66500
Completed66500
Not completed00000

Outcome measures

PrimaryChange From Baseline in Plasma HIV-1 RNA

Blood samples were taken to determine HIV-1 RNA levels at Predose (baseline) and 168 hours postdose. Data were fitted with a longitudinal data analysis (LDA) model containing fixed effects for treatment, time and treatment by time interaction, and a random effect for participant.The change from baseline in plasma HIV-1 RNA in participants administered MK-8527 was calculated and results were compared with historical placebo data.

Time frame:
Baseline and 168 hours postdose
Reported as:
Least squares mean · log10 copies/mL
Change From Baseline in Plasma HIV-1 RNA
log10 copies/mLPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Change From Baseline in Plasma HIV-1 RNA-1.39 (-1.78 to -0.99)-1.66 (-2.06 to -1.27)-0.95 (-1.38 to -0.52)
Statistical analysis
  • Panel A: MK-8527 10 mg · Posterior mean difference: -1.36Posterior Probability (PP) of true mean difference in the plasma HIV-1 RNA change from baseline between MK-8527 and placebo ≤ -1.0 copies/mL was 99.72%.
  • Panel B: MK-8527 3 mg · Posterior mean difference: -1.63PP of true mean difference in the plasma HIV-1 RNA change from baseline between MK-8527 and placebo ≤ -1.0 copies/mL was 99.86%.
  • Panel C: MK-8527 1 mg · Posterior mean difference: -0.92PP of true mean difference in the plasma HIV-1 RNA change from baseline between MK-8527 and placebo ≤ -1.0 copies/mL was 9.42%.
PrimaryPercentage of Participants Who Report 1 or More Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it is considered related to the medicinal product. The percentage of participants that reported at least 1 AE will be summarized.

Time frame:
Up to 28 days
Reported as:
Number · Percentage of participants
Percentage of Participants Who Report 1 or More Adverse Events (AEs)
Percentage of participantsPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Percentage of Participants Who Report 1 or More Adverse Events (AEs)033.30
PrimaryPercentage of Participants Who Were Discontinued From the Study Due to an AE

An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it is considered related to the medicinal product. The percentage of participants that were discontinued from the study due to an AE will be summarized.

Time frame:
Up to 28 days
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were Discontinued From the Study Due to an AE
Percentage of participantsPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Percentage of Participants Who Were Discontinued From the Study Due to an AE000
SecondaryArea Under the Concentration Time Curve From Hour 0 to 168 Hours (AUC0-168) of MK-8527-TP in Peripheral Blood Mononuclear Cells (PBMC)

Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-168 of MK-8527-triphosphate (MK-8527-TP) in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% confidence intervals (CI) for the means were constructed on the natural log scale and referenced the t-distribution.

Time frame:
Predose and 4, 12, 24, 96, 120, 144, and 168 hours postdose
Reported as:
Geometric mean · hr*pmol/10^6 cells
Area Under the Concentration Time Curve From Hour 0 to 168 Hours (AUC0-168) of MK-8527-TP in Peripheral Blood Mononuclear Cells (PBMC)
hr*pmol/10^6 cellsPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Area Under the Concentration Time Curve From Hour 0 to 168 Hours (AUC0-168) of MK-8527-TP in Peripheral Blood Mononuclear Cells (PBMC)178 (140 to 226)64.1 (50.5 to 81.3)29.1 (22.4 to 37.7)
SecondaryArea Under the Concentration Time Curve From Hour 0 to Last (AUC0-last) of MK-8527-TP in PBMC

Blood samples were taken at Predose, up to approximately 28 days postdose to determine the AUC0-last of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

Time frame:
Predose and 4, 12, 24, 96, 120, 144, 168, 240, 336, 504, 672 hours or 28 days postdose
Reported as:
Geometric mean · hr*pmol/10^6 cells
Area Under the Concentration Time Curve From Hour 0 to Last (AUC0-last) of MK-8527-TP in PBMC
hr*pmol/10^6 cellsPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Area Under the Concentration Time Curve From Hour 0 to Last (AUC0-last) of MK-8527-TP in PBMC235 (182 to 302)108 (84 to 139)49.5 (37.5 to 65.3)
SecondaryArea Under the Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-8527-TP in PBMC

Blood samples were taken at Predose, up to approximately 28 days postdose to determine the AUC0-Inf of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

Time frame:
Predose and 4, 12, 24, 96, 120, 144, 168, 240, 336, 504, 672 hours or 28 days postdose
Reported as:
Geometric mean · hr*pmol/10^6 cells
Area Under the Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-8527-TP in PBMC
hr*pmol/10^6 cellsPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Area Under the Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-8527-TP in PBMC265 (206 to 342)146 (113 to 188)55.0 (41.6 to 72.8)
SecondaryMaximum Concentration (Cmax) of MK-8527-TP in PBMC

Blood samples were taken at Predose, up to approximately 28 days postdose to determine the Cmax of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

Time frame:
Predose and 4, 12, 24, 96, 120, 144, 168, 240, 336, 504, 672 hours or 28 days postdose
Reported as:
Geometric mean · pmol/10^6 cells
Maximum Concentration (Cmax) of MK-8527-TP in PBMC
pmol/10^6 cellsPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Maximum Concentration (Cmax) of MK-8527-TP in PBMC1.81 (1.40 to 2.35)0.644 (0.497 to 0.834)0.265 (0.200 to 0.352)
SecondaryTime to Cmax (Tmax) of MK-8527-TP in PBMC

Blood samples were taken at Predose, up to approximately 28 days postdose to determine the Tmax of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

Time frame:
Predose and 4, 12, 24, 96, 120, 144, 168, 240, 336, 504, 672 hours or 28 days postdose
Reported as:
Median · Hours
Time to Cmax (Tmax) of MK-8527-TP in PBMC
HoursPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Time to Cmax (Tmax) of MK-8527-TP in PBMC18.00 (12.00 to 24.00)24.00 (12.00 to 24.00)24.00 (12.00 to 96.63)
SecondaryConcentration at 168 Hours (C168) of MK-8527-TP in PBMC

Blood samples were taken at 168 hours postdose to determine the C168 of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

Time frame:
168 hours postdose for each panel
Reported as:
Geometric mean · pmol/10^6 cells
Concentration at 168 Hours (C168) of MK-8527-TP in PBMC
pmol/10^6 cellsPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Concentration at 168 Hours (C168) of MK-8527-TP in PBMC0.509 (0.371 to 0.698)0.334 (0.244 to 0.458)0.0978 (0.0692 to 0.138)
SecondaryApparent Terminal Half Life (t1/2) of MK-8527-TP in PBMC

Blood samples were taken at Predose, up to approximately 28 days postdose to determine the t1/2 of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

Time frame:
Predose and 4, 12, 24, 96, 120, 144, 168, 240, 336, 504, 672 hours or 28 days postdose
Reported as:
Geometric mean · Hours
Apparent Terminal Half Life (t1/2) of MK-8527-TP in PBMC
HoursPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Apparent Terminal Half Life (t1/2) of MK-8527-TP in PBMC117.84 ± 35.00188.66 ± 122.5210.93 ± 14.62
SecondaryArea Under the Concentration Time Curve From Hour 0 to 168 Hours (AUC0-168) of MK-8527 in Plasma

Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-168 of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose
Reported as:
Geometric mean · hr*μmol/L
Area Under the Concentration Time Curve From Hour 0 to 168 Hours (AUC0-168) of MK-8527 in Plasma
hr*μmol/LPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Area Under the Concentration Time Curve From Hour 0 to 168 Hours (AUC0-168) of MK-8527 in Plasma0.926 (0.719 to 1.19)0.152 (0.118 to 0.196)0.0189 (0.0138 to 0.0258)
SecondaryArea Under the Concentration Time Curve From Hour 0 to Last (AUC0-last) of MK-8527 in Plasma

Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-last of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose
Reported as:
Geometric mean · hr*μmol/L
Area Under the Concentration Time Curve From Hour 0 to Last (AUC0-last) of MK-8527 in Plasma
hr*μmol/LPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Area Under the Concentration Time Curve From Hour 0 to Last (AUC0-last) of MK-8527 in Plasma0.880 (0.669 to 1.16)0.121 (0.0919 to 0.159)0.0151 (0.0112 to 0.0204)
SecondaryArea Under the Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-8527 in Plasma

Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-inf of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose
Reported as:
Geometric mean · hr*μmol/L
Area Under the Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-8527 in Plasma
hr*μmol/LPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Area Under the Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-8527 in Plasma1.10 (0.794 to 1.53)0.196 (0.141 to 0.272)NA (NA to NA)
SecondaryMaximum Concentration (Cmax) of MK-8527 in Plasma

Blood samples were taken at Predose, up to 168 hours postdose to determine the Cmax of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose
Reported as:
Geometric mean · μmol/L
Maximum Concentration (Cmax) of MK-8527 in Plasma
μmol/LPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Maximum Concentration (Cmax) of MK-8527 in Plasma0.177 (0.114 to 0.276)0.0371 (0.0238 to 0.0577)0.0162 (0.00998 to 0.0264)
SecondaryTime to Cmax (Tmax) of MK-8527 in Plasma

Blood samples were taken at Predose, up to 168 hours postdose to determine the Tmax of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose
Reported as:
Median · Hours
Time to Cmax (Tmax) of MK-8527 in Plasma
HoursPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Time to Cmax (Tmax) of MK-8527 in Plasma0.50 (0.50 to 1.00)0.50 (0.50 to 1.00)0.50 (0.50 to 0.50)
SecondaryConcentration at 168 Hours (C168) of MK-8527 in Plasma

Blood samples were taken at 168 hours postdose to determine the C168 of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

Time frame:
168 hours postdose
Reported as:
Geometric mean · μmol/L
Concentration at 168 Hours (C168) of MK-8527 in Plasma
μmol/LPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Concentration at 168 Hours (C168) of MK-8527 in PlasmaNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryApparent Terminal Half Life (t1/2) of MK-8527 in Plasma

Blood samples were taken at Predose, up to 168 hours postdose to determine the t1/2 of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose
Reported as:
Geometric mean · Hours
Apparent Terminal Half Life (t1/2) of MK-8527 in Plasma
HoursPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
Apparent Terminal Half Life (t1/2) of MK-8527 in Plasma40.31 ± 60.2712.36 ± 78.23NA ± NA

Adverse events

Collected over Up to 28 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panel A: MK-8527 10 mg0/6 (0%)0/6 (0%)0/6 (0%)
Panel B: MK-8527 3 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Panel C: MK-8527 1 mg0/5 (0%)0/5 (0%)0/5 (0%)
Most frequent other events
Most frequent other events
EventPanel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mg
PharyngitisInfections and infestations0/61/60/5
DizzinessNervous system disorders0/61/60/5
InsomniaPsychiatric disorders0/61/60/5

Baseline characteristics

Panels D and E were not conducted as the scientific study objectives were met in the conducted panels.

Age, Continuous
Age, Continuous(Years)Panel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mgPanel D: ≤50 mg MK-8527Panel E: ≤50 mg MK-8527Total
Mean28.8 ± 2.333.3 ± 9.031.2 ± 5.6——31.1 ± 6.2
Sex: Female, Male
Sex: Female, Male(Participants)Panel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mgPanel D: ≤50 mg MK-8527Panel E: ≤50 mg MK-8527Total
Female210——3
Male455——14
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Panel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mgPanel D: ≤50 mg MK-8527Panel E: ≤50 mg MK-8527Total
Hispanic or Latino000——0
Not Hispanic or Latino665——17
Unknown or Not Reported000——0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Panel A: MK-8527 10 mgPanel B: MK-8527 3 mgPanel C: MK-8527 1 mgPanel D: ≤50 mg MK-8527Panel E: ≤50 mg MK-8527Total
American Indian or Alaska Native000——0
Asian000——0
Native Hawaiian or Other Pacific Islander000——0
Black or African American000——0
White665——17
More than one race000——0
Unknown or Not Reported000——0
08

Study locations

1 site
  • Matei Bals Infectious Diseases Institute ( Site 0001)
    Bucharest, 021105, Romania
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Sep 2019, 7 months.

Results were first posted in Sep 2020, 1 year after primary completion.

Of 76 industry-sponsored phase 1 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 7 months is above that.

Counting every sponsor, half of 139 studies reached it within 14 months; a quarter within 4 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2018
First posted
Aug 3, 2018
StartActual
Feb 11, 2019
Primary completionActual
Sep 26, 2019
CompletionActual
Sep 26, 2019
Results first posted
Sep 28, 2020
Last update
Sep 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03615183
Responsible party
Sponsor
First posted
Aug 3, 2018
Start date
Feb 11, 2019
Primary completion
Sep 26, 2019
Completion
Sep 26, 2019
Results posted
Sep 28, 2020
Last update
Sep 28, 2020

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alimatravir

Start the discussion